Cullinan CMO awarded 300,000 stock options

Jones Jeffrey Alan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Jones Jeffrey Alan reported acquisition or exercise transactions in this Form 4 filing.

Cullinan Therapeutics reported that its Chief Medical Officer, Jeffrey Alan Jones, received a grant of stock options covering 300,000 shares of common stock on February 18, 2026. These options vest over four years, with one-forty-eighth of the grant vesting in equal monthly installments until the fourth anniversary of the grant date.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Jones Jeffrey Alan

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	300,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 300,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cullinan Therapeutics (CGEM) disclose in this Form 4 filing?

Cullinan Therapeutics disclosed that its Chief Medical Officer, Jeffrey Alan Jones, received a stock option grant for 300,000 shares. The options vest monthly over four years, reflecting a compensation award rather than an open-market share purchase or sale.

How many stock options were granted to CGEM Chief Medical Officer Jeffrey Alan Jones?

Jeffrey Alan Jones was granted stock options covering 300,000 shares of Cullinan Therapeutics common stock. This award is reported as a derivative security and represents a grant or award acquisition, not a market transaction in existing shares.

What is the vesting schedule for Jeffrey Alan Jones’s 300,000 CGEM stock options?

The 300,000 stock options vest over four years, with one forty-eighth of the total vesting in equal monthly installments. Vesting continues until the fourth anniversary of the grant date, aligning the Chief Medical Officer’s incentives with longer-term company performance.

Does this Cullinan Therapeutics Form 4 show a stock purchase or sale by the CMO?

The Form 4 does not show a stock purchase or sale in the market. It reports an acquisition of stock options as a grant or award, meaning the Chief Medical Officer received options to buy shares in the future, subject to the vesting schedule.

What transaction code is used in the CGEM Form 4 for this option grant?

The transaction is reported with code “A,” which indicates a grant, award, or other acquisition. It is categorized as a derivative security transaction, reflecting the issuance of stock options rather than an immediate cash purchase or sale of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 05:00 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Jeffrey Alan

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	02/18/2026		A		300,000		(1)	02/18/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.